Search our team at AdventHealth Research Institute
-
NCT06072781
VS-6766-301/GOG-3097 A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe main aims of this clinical study are to: Find out if the combination of avutometinib (VS-6766) and defactinib is better at prolonging the time it takes for LGSOC to grow compared to standard of...
-
NCT05281471
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime Study
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaYou are invited to take part in a research study. This research study is studying Olvi-Vec as a possible treatment for platinum-resistant or platinum-refractory ovarian cancer including fallopian tube...
-
NCT04625270
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC).
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe main aims of this clinical study are to: (a) Find out if the best course of study treatment is to take either VS-6766 alone (monotherapy) or to take VS-6766 together (in combination) with...
-
Pilot Feasibility Study of the Interplay between the Host Gut Microbiome and Efficacy of Treatment for Epithelial Ovarian Cancer Patients Receiving IMmunotherapy
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis research is being done to see if your gut microbiome (microorganisms that live in the gut) could help as a biomarker of clinical response to immunotherapy.
-
NCT03517332
Association of ctDNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with advanced stage epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
This study is not currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Cancer ResearchTo compare the levels of ctDNA and CTCs using the SIGNATERA™ test in the peripheral blood of patients during neoadjuvant chemotherapy and after IDS for advanced stage epithelial ovarian carcinoma...